Literature DB >> 19623820

Kantian condemnation of commerce in organs.

Samuel J Kerstein1.   

Abstract

Opponents of commerce in organs sometimes appeal to Kant's Formula of Humanity to justify their position. Kant implies that anyone who sells an integral part of his body violates this principle and thereby acts wrongly. Although appeals to Kant's Formula are apt, they are less helpful than they might be because they invoke the necessity of respecting the dignity of ends in themselves without specifying in detail what dignity is or what it means to respect it, and they cite the wrongness of an agent's treating another merely as a means without clarifying conditions under which this occurs. This paper crystallizes two different approaches to the Formula of Humanity and probes when, according to them, the principle would imply that it is wrong to engage in "live donor" transactions, in which someone chooses to undergo a kidney extraction in exchange for money.

Entities:  

Mesh:

Year:  2009        PMID: 19623820     DOI: 10.1353/ken.0.0280

Source DB:  PubMed          Journal:  Kennedy Inst Ethics J        ISSN: 1054-6863


  5 in total

Review 1.  From blood donation to kidney sales: the gift relationship and transplant commercialism.

Authors:  Julian J Koplin
Journal:  Monash Bioeth Rev       Date:  2015 Jun-Sep

2.  Does organ selling violate human dignity?

Authors:  Zümrüt Alpinar-Şencan; Holger Baumann; Nikola Biller-Andorno
Journal:  Monash Bioeth Rev       Date:  2017-11

3.  Commodification and Human Interests.

Authors:  Julian J Koplin
Journal:  J Bioeth Inq       Date:  2018-05-25       Impact factor: 1.352

4.  Ethics of Buying DNA.

Authors:  Julian J Koplin; Jack Skeggs; Christopher Gyngell
Journal:  J Bioeth Inq       Date:  2022-07-19       Impact factor: 2.216

5.  Would government compensation of living kidney donors exploit the poor? An empirical analysis.

Authors:  Philip J Held; Frank McCormick; Glenn M Chertow; Thomas G Peters; John P Roberts
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.